0000950170-24-023330.txt : 20240229 0000950170-24-023330.hdr.sgml : 20240229 20240229180158 ACCESSION NUMBER: 0000950170-24-023330 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240227 FILED AS OF DATE: 20240229 DATE AS OF CHANGE: 20240229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bizily Scott CENTRAL INDEX KEY: 0001920738 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39782 FILM NUMBER: 24705657 MAIL ADDRESS: STREET 1: C/O 4D MOLECULAR THERAPEUTICS, INC. STREET 2: 5858 HORTON STREET #455 CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 4D Molecular Therapeutics, Inc. CENTRAL INDEX KEY: 0001650648 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473506994 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5858 HORTON STREET #455 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5105052680 MAIL ADDRESS: STREET 1: 5858 HORTON STREET #455 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc. DATE OF NAME CHANGE: 20200506 FORMER COMPANY: FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc DATE OF NAME CHANGE: 20150811 4 1 ownership.xml 4 X0508 4 2024-02-27 0001650648 4D Molecular Therapeutics, Inc. FDMT 0001920738 Bizily Scott C/O 4D MOLECULAR THERAPEUTICS, INC. 5858 HORTON STREET #455 EMERYVILLE CA 94608 false true false false Chief Legal Officer true Common Stock 2024-02-27 4 M false 1909 20.24 A 3646 D Common Stock 2024-02-27 4 S false 1909 30.00 D 1737 D Stock Option (Right To Buy) 20.24 2024-02-27 4 M false 1909 0 D 2032-06-17 Common Stock 1909 48091 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. By: /s/ Scott Bizily 2024-02-29